Literature DB >> 24907399

LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

A Raquel Esteves1, Russell H Swerdlow2, Sandra M Cardoso3.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is a large, ubiquitous protein of unknown function. Mutations in the gene encoding LRRK2 have been linked to familial and sporadic Parkinson's disease (PD) cases. The LRRK2 protein is a single polypeptide that displays GTPase and kinase activity. Kinase and GTPase domains are involved in different cellular signaling pathways. Despite several experimental studies associating LRRK2 protein with various intracellular membranes and vesicular structures such as endosomal/lysosomal compartments, the mitochondrial outer membrane, lipid rafts, microtubule-associated vesicles, the golgi complex, and the endoplasmic reticulum its broader physiologic function(s) remain unidentified. Additionally, the cellular distribution of LRRK2 may indicate its role in several different pathways, such as the ubiquitin-proteasome system, the autophagic-lysosomal pathway, intracellular trafficking, and mitochondrial dysfunction. This review discusses potential mechanisms through which LRRK2 may mediate neurodegeneration and cause PD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intracellular traffic; LRRK2; Mitochondria; Parkinson's disease; Quality control mechanisms

Mesh:

Substances:

Year:  2014        PMID: 24907399      PMCID: PMC4194231          DOI: 10.1016/j.expneurol.2014.05.025

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  168 in total

1.  Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.

Authors:  Denise M Kay; Patricia Kramer; Don Higgins; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

2.  LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis.

Authors:  Samer Matta; Kristof Van Kolen; Raquel da Cunha; Geert van den Bogaart; Wim Mandemakers; Katarzyna Miskiewicz; Pieter-Jan De Bock; Vanessa A Morais; Sven Vilain; Dominik Haddad; Lore Delbroek; Jef Swerts; Lucía Chávez-Gutiérrez; Giovanni Esposito; Guy Daneels; Eric Karran; Matthew Holt; Kris Gevaert; Diederik W Moechars; Bart De Strooper; Patrik Verstreken
Journal:  Neuron       Date:  2012-09-20       Impact factor: 17.173

3.  LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool.

Authors:  Giovanni Piccoli; Steven B Condliffe; Matthias Bauer; Florian Giesert; Karsten Boldt; Silvia De Astis; Andrea Meixner; Hakan Sarioglu; Daniela M Vogt-Weisenhorn; Wolfgang Wurst; Christian Johannes Gloeckner; Michela Matteoli; Carlo Sala; Marius Ueffing
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

4.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

5.  Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

Authors:  Anthony A Estrada; Xingrong Liu; Charles Baker-Glenn; Alan Beresford; Daniel J Burdick; Mark Chambers; Bryan K Chan; Huifen Chen; Xiao Ding; Antonio G DiPasquale; Sara L Dominguez; Jennafer Dotson; Jason Drummond; Michael Flagella; Sean Flynn; Reina Fuji; Andrew Gill; Janet Gunzner-Toste; Seth F Harris; Timothy P Heffron; Tracy Kleinheinz; Donna W Lee; Claire E Le Pichon; Joseph P Lyssikatos; Andrew D Medhurst; John G Moffat; Susmith Mukund; Kevin Nash; Kimberly Scearce-Levie; Zejuan Sheng; Daniel G Shore; Thuy Tran; Naimisha Trivedi; Shumei Wang; Shuo Zhang; Xiaolin Zhang; Guiling Zhao; Haitao Zhu; Zachary K Sweeney
Journal:  J Med Chem       Date:  2012-10-15       Impact factor: 7.446

6.  Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Authors:  Edward D Plowey; Salvatore J Cherra; Yong-Jian Liu; Charleen T Chu
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

7.  The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.

Authors:  Tatsunori Maekawa; Sayuri Mori; Yui Sasaki; Takashi Miyajima; Sadahiro Azuma; Etsuro Ohta; Fumiya Obata
Journal:  Mol Neurodegener       Date:  2012-04-25       Impact factor: 14.195

8.  Regulation of LRRK2 expression points to a functional role in human monocyte maturation.

Authors:  Jonathan Thévenet; Rosanna Pescini Gobert; Robertus Hooft van Huijsduijnen; Christoph Wiessner; Yves Jean Sagot
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

9.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

10.  Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.

Authors:  M J Hurley; P H Patel; M J Jackson; L A Smith; S Rose; P Jenner
Journal:  Eur J Neurosci       Date:  2007-07       Impact factor: 3.386

View more
  38 in total

1.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

2.  Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.

Authors:  Miguel Mendivil-Perez; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio
Journal:  Neurochem Res       Date:  2016-07-09       Impact factor: 3.996

Review 3.  In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  Stem Cells Dev       Date:  2018-03-29       Impact factor: 3.272

Review 4.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

Review 5.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

6.  lncRNA MALAT1/miR-205-5p axis regulates MPP+-induced cell apoptosis in MN9D cells by directly targeting LRRK2.

Authors:  Qin Chen; Xiaoyan Huang; Renjie Li
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

7.  Association of LRRK2 Haplotype With Age at Onset in Parkinson Disease.

Authors:  Bin Xiao; Xiao Deng; Ebonne Yu-Lin Ng; John Carson Allen; Shen-Yang Lim; Azlina Ahmad-Annuar; Eng-King Tan
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

8.  LRRK2: An Emerging New Molecule in the Enteric Neuronal System That Quantitatively Regulates Neuronal Peptides and IgA in the Gut.

Authors:  Tatsunori Maekawa; Hitomi Shimayama; Hiromichi Tsushima; Fumitaka Kawakami; Rei Kawashima; Makoto Kubo; Takafumi Ichikawa
Journal:  Dig Dis Sci       Date:  2017-02-06       Impact factor: 3.199

9.  Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.

Authors:  Siyu Wu; Lili Lei; Yang Song; Mengting Liu; Shibo Lu; Dan Lou; Yonghong Shi; Zhibin Wang; Defu He
Journal:  Exp Neurol       Date:  2018-08-01       Impact factor: 5.330

10.  The Impact of Mitochondrial Fusion and Fission Modulation in Sporadic Parkinson's Disease.

Authors:  Daniel Santos; A Raquel Esteves; Diana F Silva; Cristina Januário; Sandra M Cardoso
Journal:  Mol Neurobiol       Date:  2014-09-14       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.